News & media
Recent press releases
-
Publications
CuraCell completes CytoPLY™ named-patient publication series
opens in a new tabCuraCell publishes third and final clinical report from CytoPLY™ named-patient program, demonstrating tumour responses across multiple difficult-to-treat solid tumours.
Cision
-
Company
CuraCell welcomes two new board members
opens in a new tabCuraCell strengthens board of directors with appointment of Thomas Jaecklin and Martin Forster.
Cision
-
Clinical trial
CuraCell announces first patient included in clinical trial of innovative TIL therapy CC-38
First patient has been successfully included in the ongoing phase I/IIa clinical trial evaluating CuraCell’s autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer. Read t...
CuraCell news and media
-
TIL therapy
Featured in Clinical Leader: CuraCell's Head of Clinical Operations, Torbjörn Ström, on rethinking the future of TIL therapy.
opens in a new tabWhat if TIL therapy could be less burdensome for patients, more cost-efficient to produce, and effective against tumors that have traditionally been difficult to treat?
Clinical Leader
-
TIL therapy
CuraCell featured by Labiotech among innovators redefining TIL for solid tumors
opens in a new tabCuraCell is featured as one of the key innovators in Labiotech's article highlighting the growing momentum of tumor-infiltrating lymphocyte (TIL) therapy as a solution to solid tumors.
Labiotech
-
Clinical research
CuraCell joins discussion on the future of SweTrial and clinical research in Sweden
opens in a new tabCuraCell joined a KI Science Park panel discussion on SweTrial and boosting clinical trials in Sweden.
CuraCell on LinkedIn
-
Cell therapy
CuraCell CEO shares perspective on the future of cell therapy
opens in a new tabCuraCell CEO Jonas Båtelson shares his perspective on the rapidly evolving immuno-oncology landscape in a recent feature published by Citeline Industry Insights.
Citeline Industry Insights
-
Research
CuraCell’s research on potent, tumour-targeted T cells
opens in a new tabCuraCell’s research is focused on engineering highly potent, tumour-targeted T cells with improved activation and tumour-homing capabilities — helping immune cells infiltrate and function within the hostile solid-tumour microenvironment.
Citeline
-
TIL therapy
BioStock highlights CuraCell's progress toward clinical development of TIL therapy
opens in a new tabBioStock has featured CuraCell's latest scientific and clinical progress, highlighting the company's tumor-infiltrating lymphocyte (TIL) platform and its potential to address difficult-to-treat solid tumors.
BioStock
-
Awareness
CuraCell supports prostate cancer awareness through Mustaschmilen
opens in a new tabCuraCell participated in the Mustaschmilen Run, joining thousands of participants to raise awareness of prostate cancer and supporting efforts to improve outcomes for patients living with the disease.
CuraCell on LinkedIn
-
Publications
CuraCell study demonstrates long-term immune control achieved in prostate cancer
CuraCell is proud to announce the publication of its latest research article,“Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer,”in the peer-reviewed journal Frontiers in Oncology. The study provides novel i...
-
Publications
CuraCell research publication highlights tumor regression driven by tumor-infiltrating lymphocytes in glioblastoma
CuraCell is proud to announce the acceptance of its latest research article, “Tumor-infiltrating lymphocytes-derived CD8⁺clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma,”in the leading peer-reviewed journal OncoImm...
-
Regulatory
CuraCell receives CTA approval for phase I/IIa clinical trial with innovative TIL therapy CC-38
CuraCell today announced that the Paul-Ehrlich-Institut (PEI), the German federal authority for vaccines and biomedicines, has approved the company’s Clinical Trial Application (CTA) to initiate a Phase I/IIa clinical trial evaluating its novel autol...
-
Manufacturing
CuraCell partners with ScaleReady in cGMP manufacturing optimization
CuraCell signed a collaboration agreement with ScaleReady under the G-REX Grant Program Initiative aimed to advance state of the art cell and gene-modified cell therapy (CGT) development and manufacturing. ScaleReady, with support from Wilson Wolf Co...
-
Conferences
CuraCell to present patient named clinical results at AACR and ISCT 2025 in the USA
CuraCell will present clinical outcomes of patients treated with our Tumor Infiltrating Lymphocytes (TIL)-based therapy this spring at the American Association for Cancer Research (AACR) Annual Meeting and the International Society for Cell & Gene Th...
-
Manufacturing
CuraCell's CDMO partner Zellwerk-Berlin receives GMP licence
CuraCell’s manufacturing partner Zellwerk-Berlin GmbH, a specialized contract development & manufacturing organization (CDMO), receives GMP authorization of its manufacturing site in Brandenburg, Germany. The GMP authorization of Zellwerk-Berlin’s si...
-
Regulatory
CuraCell holds final advice meeting with German regulator PEI
CuraCell today held its second advice meeting with the German regulator PEI (Paul-Ehrlich Institut). The first meeting was held on the 27th of October, focused on non-clinical questions related to the company’s first product, CC-38. Today’s meeting w...
-
Clinical trial
CuraCell selects IKF as CRO partner for its phase 1/2a trial
CuraCell has signed a partnership agreement with the German Clinical Research Organisation, IKF, located in Frankfurt, Germany. IKF will support CuraCell in the preparation of the upcoming phase 1/2a trial and coordinate clinical operations throughou...
-
Manufacturing
CuraCell signs collaboration agreement with Zellwerk-Berlin
Takura’s affiliate CuraCell signed a collaboration agreement with Zellwerk-Berlin, a Specialized Contract Development & Manufacturing Organization (CDMO) with engagements in Tumor Infiltrating Lymphocytes (TIL), Natural Killer (NK) cells and Mesenchy...